摘要
目的验证奎硫平(思瑞康)治疗精神分裂症患者的临床疗效与安全性。方法将60例精神分裂症患者随机分为思瑞康组(30例)和氯丙嗪组(30例),分别给予思瑞康与氯丙嗪治疗4周,采用阳性症状与阴性症状量表(PANSS)评定临床疗效,以副反应量表(TESS)记录不良反应。结果两组PANSS评分较治疗前均有显著下降(P<0.01);临床总有效率思瑞康组为83.3%,氯丙嗪组为86.6%,两组间疗效比较无显著性差异(P>0.05);思瑞康组的各种不良反应发生率均较氯丙嗪组低(P<0.05)。结论奎硫平与氯丙嗪治疗精神分裂症的疗效相似,但不良反应较氯丙嗪少,在改善认知功能和阴性症状方面也优于氯丙嗪,更有益于全程治疗。
Objective To explore the efficacy and safety of Seroquel in the treatment of schizophrenia. Methods A total of 60 patients with schizophrenia were randomly allocated to Seroquel group （30 cases） anti chlorpromazine group （30 cases）. Seroquel and chlorpromazine were used respectively. All patients were treated for 4 weeks. Efficacy in schizophrenia was determined using the PANSS scale. Safety was evaluated using TESS scale. Results PANSS scale in end point was decreased significantly than baseline in both groups （P 〈 0. 01）. Remission rate was 83.3% in Seroquel group and 86.6% in chlorpromazine group. No significant difference existed within treatment groups（P〉0.05）. The adverse effect in Seroquel group was significantly less and lighter than chlorpromazine group （P〈 0. 05）. Conclusion No significant difference between Seroquel and chlorpromazine groups was observed for efficacy. Seroquel, which has less adverse effect, more ability to improve the cognitive function and negative symptom than chlorpromazine, is an effective and safe antipsychotic drug and beneficial to whole course treatment.
出处
《中国药业》
CAS
2007年第19期56-57,共2页
China Pharmaceuticals
关键词
思瑞康
氯丙嗪
精神分裂症
疗效
Seroquel
chlorpromazine
sehizophrenia
therapeutic effect
